Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

usiness strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-K. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 DuPont Pioneer announced ... as vice president of Agricultural Biotechnology (ABT), effective July ... he served most recently as president, chief executive officer ... business leadership in the seed and crop protection industry ... Paul E. Schickler , president of DuPont Pioneer. “I ...
(Date:7/23/2014)... , July 23, 2014  Sofinnova Ventures, a ... announced the closing of Sofinnova Venture Partners IX, L.P. ... excess of the initial fund target of $425 million. ... successful biotechnology companies. Consistent with recent funds, SVP IX ... stage clinical programs, along with select investments in earlier ...
(Date:7/23/2014)... Adult stem cells that are required ... not magical. However, many current regenerative medicine ... if they were magical. , Many current clinical ... “stem cell tourism,” are evaluating heterologous tissue stem ... regenerative medicine therapies. In reality, these are not ...
(Date:7/22/2014)... of Standards and Technology (NIST) and California Institute ... for an atomic clock that is based on ... The microcomb clock, featured on the cover of ... Optica ,* is the first demonstration of all-optical ... of optical frequencies to lower microwave frequencies. (Optical ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5'Comb on a chip' powers new NIST/Caltech atomic clock design 2
... work showing how nanowires carved in impurity-laden diamond ... developed a scalable manufacturing process to craft arrays ... photon control. The development supports efforts to ... stage for diamond-based microchips. Additionally, the technology ...
... 2011 Applied Precision is proud to announce ... super-resolution microscopy system at McGill University in Montreal, ... is a super-resolution microscope utilizing proven three-dimensional structured ... in volume resolution and outstanding widefield imaging capabilities. ...
... Ohio, Oct. 18, 2011 Minimally Invasive Devices, Inc ... new product, FloShield PLUS , utilizing the novel Flo-X ... of the end of the laparoscope without removal from the ... MID,s FloShield laparoscopic visualization system. In the first 19 FloShield ...
Cached Biology Technology:Diamonds, silver and the quest for single photons 2Diamonds, silver and the quest for single photons 3Applied Precision Announces the 25th Installation of Its DeltaVision OMX Super-Resolution Microscope at McGill University 2
(Date:7/23/2014)... Tracking of blue whales by satellite over a 15-year ... whales consistently return to feed in specific locations each ... in the open-access journal PLOS ONE by ... data may be used to mitigate human threats to ... has been slow to recover since the establishment of ...
(Date:7/23/2014)... cystic fibrosis patients, scientists at the UNC School of ... that a new CF drug counteracts the intended beneficial ... published today in the journal Science Translational Medicine ... and loses its ability to function properly when in ... several insights into how novel CF pharmacotherapies could be ...
(Date:7/23/2014)... , , , , , ... , , , , ... diseases and extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... several proteins in mice that might act as biomarkers ... step to finding a more reliable way to detect ... teenagers use illegally to boost muscle and reduce fat. ... San Francisco today, scientists John Kopchick and Juan Ding ...
... the White House must be enhanced so that the ... nationfrom energy and the environment, to national security, and ... collaborate internationally. The report,s primary recommendations are that: ... respected leader to be Assistant for Science and Technology ...
... 2008 Mary Tyler Moore, the Juvenile Diabetes Research ... M.D., presented the sixth annual "Excellence in Clinical Research ... annual conference today in Washington, DC. The recipients ... director of the JDRF Gene Therapy Center for Diabetes ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2White House science office needs upgrade 2White House science office needs upgrade 3Florida researchers receive JDRF 'Excellence in Clinical Research Award' 2